Leerink Partners analyst Andrew Berens has maintained their bullish stance on ZYME stock, giving a Buy rating yesterday.
Andrew Berens has given his Buy rating due to a combination of factors including the promising outlook for Zymeworks’ zanidatamab program. The anticipated readout for the 1L HER2+ GEA trial is expected in the second half of 2025, which could potentially indicate strong performance of the experimental arms compared to the standard of care. This suggests a positive trajectory for the company’s flagship product.
Additionally, Zymeworks’ strategic focus on advancing other promising candidates like ZW251, while managing resources effectively, demonstrates a robust pipeline strategy. The company’s financial position, with a cash runway extending into the second half of 2027, further supports the Buy rating as it indicates financial stability and the ability to continue funding its development programs.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $19.00 price target.
ZYME’s price has also changed slightly for the past six months – from $11.560 to $12.130, which is a 4.93% increase.
Questions or Comments about the article? Write to editor@tipranks.com